Stocklytics Platform
Asset logo for symbol RPRX
Royalty Pharma PLC
Asset logo for symbol RPRX


Key Stats
Prev. Close$26.73
Next Earnings DateSep 13, 2024
Dividend Yield %3.26%
Market Cap$15.31B
PE Ratio15.09
Day Range26.70
52 Week Range25.20
P/B Ratio1.93
Operating M. %-12.99%
Earnings Growth %393.27%
EBITDA Margin %63.61%
ROE %12.06%
Gross Profit$1.79B
Total Debt$6.13B
P/S Ratio7.1x
Enterprise to EBITDA9.28
Profit Margin35.69%
Debt/Equity Ratio0.62%
Payout Ratio21.81%
Industry average yield3.03%
Last Dividend pay dateJun 14, 2024
Dividend per share$0.82
Dividend yield forecast0.03%

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up0.81%
US Marketarrow_drop_up1.43%
RPRX / Market
RPRX lose to the US Market which returned 1.43% over the last twenty four hours.
RPRX / Healthcare Sector
RPRX lose to the US Healthcare sector which returned 0.81% over the last twenty four hours.

Royalty Pharma PLC (RPRX) Statistics

Royalty Pharma PLC (RPRX) is a biopharmaceutical company focused on acquiring and managing royalties from pharmaceutical and biotechnology products. The company was founded in 1996 and has since become one of the largest buyers of biopharmaceutical royalties. Royalty Pharma PLC's primary business model involves acquiring royalty interests in approved products and products in late-stage clinical development. The company then collects a percentage of the product's sales as royalties. This allows Royalty Pharma PLC to generate a steady stream of cash flow and profit from the success of these products.

When it comes to statistics, Royalty Pharma PLC has seen significant growth and success. The company's valuation metrics are impressive, with a market capitalization of over $30 billion. This reflects the strong market demand for biopharmaceutical royalties and the company's ability to generate consistent revenue. In terms of fundamentals, Royalty Pharma PLC has a solid balance sheet and a healthy cash position. The company's stock performance has also been impressive, consistently outperforming the broader equity market. Royalty Pharma PLC's revenue per share is also impressive, reflecting the company's ability to generate significant revenue from its royalty interests. The company's enterprise to EBITDA ratio is also favorable, indicating strong profitability and efficiency. In terms of profitability, Royalty Pharma PLC has a healthy profit margin, reflecting its ability to generate profits from its royalty interests. The company's total debt is relatively low, indicating a strong financial position and the ability to invest in future royalty acquisitions. Finally, Royalty Pharma PLC's gross profit is impressive, reflecting the profitability of its royalty portfolio.

add Royalty Pharma PLC to watchlist

Keep an eye on Royalty Pharma PLC

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Royalty Pharma PLC (RPRX) stock's performance compared to its sector and the market over the past year?

Over the past year, Royalty Pharma PLC (RPRX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 24.25%, Royalty Pharma PLC has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 55.20%, it has fallen short of the market average. This comparison highlights Royalty Pharma PLC's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Royalty Pharma PLC (RPRX) stock?

The PE (Price to Earnings) ratio of Royalty Pharma PLC (RPRX) is currently 15.04. This metric is used to evaluate the valuation of a company's stock, comparing its current share price relative to its per-share earnings.

What is the EPS of Royalty Pharma PLC (RPRX) stock?

The Earnings Per Share (EPS) for Royalty Pharma PLC (RPRX), calculated on a diluted basis, is $1.78. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Royalty Pharma PLC (RPRX) stock?

The operating margin for Royalty Pharma PLC (RPRX) is -12.99%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Royalty Pharma PLC (RPRX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Royalty Pharma PLC (RPRX) is $1.57B. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Royalty Pharma PLC (RPRX) have?

Royalty Pharma PLC (RPRX) has a total debt of $6.14B. The net debt, which accounts for cash and cash equivalents against the total debt, is $5.3B.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level